Skip to main content
Top
Published in:

01-03-2010 | Short Communication

Acute gastric lesions induced by the administration of histamine to rats with partial vascular occlusion: evidence for the gastroprotective effect of prostaglandin

Authors: P. C. Konturek, T. Brzozowski, M. Raithel, Z. Sliwowski, S. J. Konturek, M. F. Neurath

Published in: Inflammation Research | Special Issue 2/2010

Login to get access

Abstract

Introduction

Histamine is not only a potent stimulator of gastric acid secretion, but it also plays a central role in gastroduodenal ulcerogenesis. In the present study we tested the effect of pre-treatment with exogenous prostaglandin E2 (PGE2) in a new rat model of experimental gastric ulcers induced by combination of histamine and gastric ischemia.

Methods

In male Wistar rats, a chronic ischemia of gastric mucosa was induced via the clamping of the left gastric artery and vein (L-AV) in combination with pylorus ligation. The following treatment groups of rats (6 rats/group) were investigated: 1) histamine alone (40 mg/kg twice s.c.); 2) vehicle (saline) followed 30 min later by gastric mucosal L-AV ischemia and pylorus ligation combined with histamine (40 mg/kg twice s.c.) and 3) PGE2 (5 µg/kg i.g.) followed 30 min later by gastric mucosal L-AV ischemia combined with histamine (40 mg/kg twice s.c.) and pylorus ligation. At 4 hr after the clamping of L-AV and pylorus ligation, the area of gastric lesions and gastric acid secretion was determined.

Results

Histamine treatment failed to produce gastric lesions, but when it was combined with ischemia, the widespread gastric lesions in the corpus mucosa, but not in the antrum, were observed. This damaging effect and decrease in the GBF were significantly attenuated by pretreatment with PGE2.

Conclusion

The present study demonstrates that gastric hypersecretion induced by histamine in combination with gastric mucosal ischemia results in gastric lesions which progress into chronic gastric ulcers.
Literature
1.
go back to reference Hakanson R, Sundler F. Histamine-producing cells in the stomach and their role in the regulation of acid secretion. Scand J Gastroenterol. 1991;26:88–94.CrossRef Hakanson R, Sundler F. Histamine-producing cells in the stomach and their role in the regulation of acid secretion. Scand J Gastroenterol. 1991;26:88–94.CrossRef
2.
go back to reference Eagleton GB, Watt J. The selective production of gastric and duodenal ulceration using histamine. In: Pfeiffer CJ, editor. Peptic ulcer. Philadelphia: JB Lippincott; 1971. p. 34–44. Eagleton GB, Watt J. The selective production of gastric and duodenal ulceration using histamine. In: Pfeiffer CJ, editor. Peptic ulcer. Philadelphia: JB Lippincott; 1971. p. 34–44.
3.
go back to reference Amagase K, Okabe S. On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. J Pharmacol Sci. 2003;92:124–36.CrossRefPubMed Amagase K, Okabe S. On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. J Pharmacol Sci. 2003;92:124–36.CrossRefPubMed
4.
go back to reference Brzozowski T, PCh Konturek, Konturek SJ, Sliwowski Z, Drozdowicz D, Stachura J, et al. Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol. 1999;385:47–61.CrossRefPubMed Brzozowski T, PCh Konturek, Konturek SJ, Sliwowski Z, Drozdowicz D, Stachura J, et al. Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol. 1999;385:47–61.CrossRefPubMed
5.
go back to reference Robert A. Cytoprotection by prostaglandins. Gastroenterology. 1979;77:761–7.PubMed Robert A. Cytoprotection by prostaglandins. Gastroenterology. 1979;77:761–7.PubMed
6.
go back to reference Gerber JG, Nies AS. The role of prostaglandins in histamine-induced gastric vasodilatation in the dog. J Pharmacol Exp Ther. 1980;213:79–84.PubMed Gerber JG, Nies AS. The role of prostaglandins in histamine-induced gastric vasodilatation in the dog. J Pharmacol Exp Ther. 1980;213:79–84.PubMed
7.
go back to reference Kato S, Takeuchi K, Okabe S. Mechanism by which histamine increases gastric mucosal blood flow in the rat. Role of luminal H+. Dig Dis Sci. 1993;38:1224–32.CrossRefPubMed Kato S, Takeuchi K, Okabe S. Mechanism by which histamine increases gastric mucosal blood flow in the rat. Role of luminal H+. Dig Dis Sci. 1993;38:1224–32.CrossRefPubMed
Metadata
Title
Acute gastric lesions induced by the administration of histamine to rats with partial vascular occlusion: evidence for the gastroprotective effect of prostaglandin
Authors
P. C. Konturek
T. Brzozowski
M. Raithel
Z. Sliwowski
S. J. Konturek
M. F. Neurath
Publication date
01-03-2010
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue Special Issue 2/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-009-0140-5

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar